The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis
Open accessAbstract
Objectives This study was conducted to define the association between serum B-type natriuretic peptide (BNP) activation and survival after the diagnosis of aortic stenosis (AS).Background In AS, the link between BNP levels and clinical outcome is in dispute. Failure to account for the normal shifting of BNP ranges with aging in men and women, not using hard endpoints (survival), and not enrolling large series of patients have contributed to the uncertainty.Methods A program of prospective measurement of BNP levels with Doppler echocardiographic AS assessment during the same episode of care was conducted. BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1 defined BNP clinical activation.Results In 1,953 consecutive patients with at least moderate AS (aortic valve area 1.03 ± 0.26 cm(2); mean gradient 36 ± 19 mm Hg), median BNP level was 252 pg/ml (interquartile range: 98 to 592 pg/ml); BNP ratio 2.46 (interquartile range 1.03 to 5.66); ejection fraction (EF) 57% ± 15%, and symptoms present in 60% of patients. After adjustment for all survival determinants, BNP clinical activation (BNP ratio >1) independently predicted mortality after diagnosis (p < 0.0001; hazard ratio [HR]: 1.91; 95% CI: 1.55 to 2.35) and provided incremental power to the survival predictive model (p < 0.0001). Eight-year survival was 62 ± 3% with normal BNP levels, 44 ± 3% with BNP ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to 1.90), 25 ± 4% with BNP ratio of 2 to 3 (adjusted HR: 2.12; 95% CI: 1.63 to 2.75), and 15 ± 2% with BNP ratio of ≥3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.05). This strong link to survival was confirmed in asymptomatic patients with normal EF (adjusted HR: 2.35 [95% CI: 1.57 to 3.56] for BNP clinical activation and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP ratio of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP ratio of ≥3). Aortic valve replacement was associated with survival improved by a similarly high margin (p = 0.54) with BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89; p = 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47 to 0.66; p < 0.0001).Conclusions In this large series of patients with AS, BNP clinical activation was associated with excess long-term mortality incrementally and independently of all baseline characteristics. Higher mortality with higher BNP clinical activation, even in asymptomatic patients, emphasizes the importance of appropriate clinical interpretation of BNP levels in managing patients with AS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that elevated levels of brain natriuretic peptide, cardiac troponin, and galectin-3 are correlated with all-cause mortality in individuals with CAVS.6,7,8,9,10”
From Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targets (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A BNP ratio of >1 was found to be a powerful independent predictor of mortality in AS, even in patients with asymptomatic AS187.”
From Calcific aortic stenosis (2016) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008232 · Cited by 7,205
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Self-citationGuidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
Iung, B. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00201-x · Cited by 3,530
Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice
Baumgartner, H., Hung, J., Bermejo, J., Chambers, J. B., Evangelista, A., Griffin, B. P., Iung, B., Otto, C. M., Pellikka, P. A., & Quiñones, M. A. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.11.029 · Cited by 2,131
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.021 · Cited by 1,702
Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis
Rosenhek, R., Binder, T. M., Porenta, G., Lang, I. M., Christ, G., SCHEMPER, M., Maurer, G., & Baumgartner, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430903 · Cited by 1,332
Cited by
Sorted by citations
Items 201–226 of 226
Akashi, R., Koga, S., Honda, T., Satoh, D., Eguchi, C., Matsumaru, I., Yonekura, T., Yoshimuta, T., Ikeda, S., Kawano, H., et al. (2024) · Journal of Transcatheter Valve Therapies · doi:10.33290/jtvt.oa.24-0012
Hamada, M., Ogimoto, A., Otani, T., Kubota, N., Hiasa, G., & Ikeda, S. (2024) · International Heart Journal · doi:10.1536/ihj.24-044
“3) In addition, BNP has a strong prognostic value in patients with AS. 4,5) However, a recent study re-ported that the all-cause and cardiovascular-related mortality rates 2 years after TAVI were higher in patients with low and markedly elevated BNP levels.”
Costa, L. C., Guerra, M. J. G., & Teixidor, M. D. (2022) · Actualización en Medicina de Familia · doi:10.55783/amf.180804
Mao, Y., Zhai, M., Jin, P., Zhang, G., Zhang, H., Wei, L., Shang, X., Li, J., Guo, Y., Pan, X., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101770
“Therefore, this retrospective observational study analyzed changes in the NT-proBNP ratio (defined as the maximum normal value of NT-proBNP for a specific age and sex) during the short-term follow-up period [11,12].”
Complex surgical treatment of critical aortic stenosis complicated by multiple organ failure
Romanenko, N. V., Lysenko, A. V., Игоревич, С. Г., Вавилов, А. В., & Sozykin, A. (2025) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia2025121162
Lv, J., Zhang, B., Ye, Y., Li, Z., Wang, W., Zhao, Q., Liu, Q., Zhao, Z., Zhang, H., Wang, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26604529
Lv, J., Zhang, B., Ye, Y., Li, Z., Wang, W., Zhao, Q., Liu, Q., Zhao, Z., Zhang, H., Wang, B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26604526
Gotschy, A., Binter, C., Schlenker, R., Tanner, F. C., Manka, R., & Kozerke, S. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00043.2026
Carneiro, J. A., Costa, A. R., & Araujo, C. C. N. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107408
Rétrécissement aortique orificiel de l’adulte
Suc, G. (2026) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)50807-4
Impact pronostique du débit cardiaque dans la sténose valvulaire aortique
Ven, F. L. (2016) · theses.fr (ABES) · doi:10.70675/cdcaf5bcz039bz4058z83efz2e7f79bae996
“symptômes et une survie diminuée [80], [81].”
BackgroundLe rôle de l'Epoxyde hydrolase soluble (sEH) dans la physiopathologie des calcifications vasculaires
Varennes, O. (2018) · theses.fr (ABES) · doi:10.70675/d554fcf1z9f51z419bz9693z571dd887124a
MicroARNs, marqueurs de la pathologie valvulaire aortique
Nader, J. (2019) · theses.fr (ABES) · doi:10.70675/4d490f42z8b44z4281zb256zd9d9d5976dab
Rôle de l'interleukine-8 dans la progression de la calcification valvulaire aortique
Dhayni, K. (2022) · theses.fr (ABES) · doi:10.70675/468c669az786az4e56zadc0z315e6935c886
Carneiro, J. A., Costa, A. R., & Araujo, C. C. N. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2026.107408
Mizutani, K., Tanaka, A., Tokuda, Y., Kondo, H., Takeda, S., Matsumoto, H., Yamada, M., Uemura, T., Furusawa, K., Mutsuga, M., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134705
Stenosi dell'orifizio aortico negli adulti
Suc, G. (2026) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(26)52107-7
Estenosis aórtica valvular en adultos
Suc, G. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)52249-9
Hùng, P. M. (2026) · Tạp chí Tim Mạch Học Việt Nam · doi:10.58354/jvc.122.2026.1324
Demir, O. M., Latib, A., & Prendergast, B. (2026) · Open Heart · doi:10.1136/openhrt-2026-004523
Diretriz Brasileira de Valvopatias – 2026
Tarasoutchi, F., Fernandes, J. R. C., Rosa, V. E. E., Sampaio, R. O., Sepúlveda, D. P. L., Ramos, A. I. D. O., Campos, C. M., Neto, F. R. D. M., Hüning, A. R., Kiyose, A. T., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260796
Diretriz Brasileira de Cardiogeriatria – 2026
Helber, I., Zanon, J. C. D. C., Peixoto, J. M., Caixeta, A. M., Nussbacher, A., de Oliveira, D. C., de Freitas, E. V., Cintra, F. D., Garcia, J. S., Miranda, R. D., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260795
Die asymptomatische Aortenklappenstenose – wann und wie behandeln in 2026?
Grothusen, C., & Möllmann, H. (2026) · Aktuelle Kardiologie · doi:10.1055/a-2912-3706
Metadata
- Authors
- Clavel, M.-A., Malouf, J., Michelena, H. I., Suri, R. M., Jaffe, A. S., Mahoney, D. W., & Enriquez-Sarano, M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Enriquez-Sarano, Maurice
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 63
- Issue
- 19
- Pages
- 2016-2025
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W56250199
- Cited by
- 226
- References
- 48
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 10 · 2023: 20 · 2022: 19 · 2021: 16 · 2020: 29 · 2019: 19 · 2018: 17 · 2017: 24 · 2016: 17 · 2015: 15 · 2014: 5
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Funders
- Canadian Institute of Health Research
- Abbott Diagnostics
- Edwards Lifesciences
- St. Jude Medical
- Sorin Group
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Aortic Disease and Treatment Approaches
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- brain natriuretic peptide, aortic stenosis, mortality prediction, survival after diagnosis, asymptomatic aortic stenosis, ejection fraction, Doppler echocardiography, prognostic factors, heart failure risk stratification, heart failure hospitalization, heart failure mortality, heart failure readmission
- MeSH terms
- Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Time Factors, Cohort Studies, Biomarkers, Survival Rate, Natriuretic Peptide, Brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
